India's Health Ministry Proposes Requiring Government Approval for Pharmacy and Wholesaler Ads of Prescription Drugs

India's Health Ministry wants to close a gap in its drug advertising rules, and the target is the corner chemist as much as the drug company.

The draft amendment was notified in the Gazette as G.S.R. 861(E) on September 28, 2026. The ministry publicized it Friday, October 9.

What the draft would do

The ministry proposes adding sub-rule (22) to Rule 65 of the Drugs Rules, 1945. The text says no advertisement of drugs in Schedule H, H1 or X may be made without the previous sanction of the Central Government.

The provision would apply to anyone holding a licence to sell, stock, exhibit, offer for sale or distribute those drugs. That covers retail pharmacies, wholesalers and distributors. Online pharmacy platforms would also fall under the rule.

Schedules H, H1 and X cover medicines that require a prescription and medical supervision. They include certain antibiotics and psychotropic drugs. Reporting on the proposal also lists hormonal preparations, anti-cancer medicines, narcotic drugs and life-saving injectables among the categories regulators have flagged.

The gap

Manufacturers are already barred from advertising these drugs without prior central approval. The existing rules did not explicitly reach the people who sell them.

That distinction is the core of the amendment. Government sources told India Today the gap meant no action could be taken against pharmacies advertising blockbuster drugs and offering discounts on them. In recent months those drugs have included GLP-1-based medicines such as Mounjaro, Ozempic and Wegovy.

The ministry's stated aims, in its own words: to "strengthen regulatory oversight across the pharmaceutical supply chain, discourage unauthorized promotion of prescription medicines and reduce risks associated with inappropriate self-medication."

Advertising these drugs was not a free-for-all before. The prior-sanction requirement already existed for the schedules. The change is who it binds.

The GLP-1 backdrop

GLP-1 drugs were developed for type 2 diabetes. They are now also used for weight loss, and India Today reports the market has grown rapidly over recent months.

The proposal lands after a run of regulatory moves on these drugs. In March 2026, the Central Drugs Standard Control Organisation (CDSCO) stepped up surveillance of the GLP-1 supply chain. According to the Health Ministry, inspections covered 49 entities, including online pharmacy warehouses, wholesalers, retailers, wellness centres and slimming clinics. The targets were unauthorised sales, improper prescribing and misleading marketing.

On March 10, 2026, the CDSCO issued an advisory barring surrogate and indirect promotion. That includes campaigns dressed up as obesity awareness, influencer collaborations or general weight-management talk that build demand for a specific prescription product.

About three weeks ago the government also proposed CCTV surveillance at licensed retail premises selling prescription drugs, with recordings kept for three months.

Doctors back it

Dr Reshu Agarwal, an internal medicine specialist at Yathartha Super Speciality Hospital in Noida, called the move much needed. "It is highly possible that patients get influenced by the advertisements and forget the importance of getting the correct prescription, dosage, and side effects information," she said. She added that prescription drugs should only be taken under a doctor's supervision because needs differ from person to person.

No objection from chemists, wholesalers or drug distributors has surfaced yet. The 30-day comment window is where any pushback would be filed.

The government-approval question

The design is notable. The draft does not ban pharmacy advertising of these drugs outright. It routes every such advertisement through a central government sanction, the same mechanism already applied to manufacturers. How often sanction would be granted, and on what criteria, is not spelled out in the notice.

That is a lot of discretion placed in a central office. A rule meant to protect patients also adds another permission layer for tens of thousands of small licensed businesses. Whether the ministry intends to approve any retailer advertising of these drugs, or effectively prohibit it, has not been stated.

Timeline and next steps

The proposal follows recommendations from the 93rd meeting of the Drugs Technical Advisory Board on February 16, 2026, which examined rules for advertising by sale and distribution licence holders.

The ministry has invited objections and suggestions from stakeholders and the public within 30 days of the date the Gazette copies are made available to the public. It says it will consider all submissions received in that window before the amendment is finalised.

The open question is what the final text looks like. Chemists and wholesalers now have a month to argue for carve-outs, and the ministry has yet to say how sanction requests would be processed.